Skip to main content
Erschienen in: Journal of Gastroenterology 8/2019

15.02.2019 | Original Article—Alimentary Tract

A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report

verfasst von: Toshihiko Kakiuchi, Muneaki Matsuo, Hiroyoshi Endo, Aiko Nakayama, Keiko Sato, Ayako Takamori, Kazumi Sasaki, Mitsuhiro Takasaki, Megumi Hara, Yasuhisa Sakata, Masumi Okuda, Shogo Kikuchi, Yuichiro Eguchi, Hirokazu Takahashi, Keizo Anzai, Kazuma Fujimoto

Erschienen in: Journal of Gastroenterology | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

To present the strategies and preliminary findings of the first 3 years after implementing a Helicobacter pylori screening and eradication program to prevent gastric cancer in Saga Prefecture.

Methods

A screening and treatment program to eradicate H. pylori from third-grade junior high students was started in Saga Prefecture in 2016, using local governmental grants. Screening was with urinary anti-H. pylori antibody tests, followed by H. pylori stool antigen tests for students who were antibody positive. Those positive on both tests underwent H. pylori eradication by triple therapy based on a potassium-competitive acid blocker.

Results

From 2016 to 2018, the participation rate was 83.1% and the H. pylori infection rate was 3.1% (660/21,042). The participation rates were higher in 2017 (85.4%) and 2018 (85.9%) compared with 2016 (78.5%) (P < 0.0001), and the infection rate also decreased in a time-dependent manner (2016: 3.6%, 2017: 3.3%, 2018: 2.5%, P = 0.0001). In total, 501 students positive for H. pylori received eradication therapy (85.1% success) and adverse events occurred in 20 of these (4.0%). However, no serious complications occurred.

Conclusions

The H. pylori screening and eradication project for school students in Saga Prefecture has started successfully and we have seen both a steady increase in the participation rate and a steady decrease in the infection rate, without major safety concerns.
Literatur
1.
Zurück zum Zitat Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.CrossRefPubMed
2.
Zurück zum Zitat Park JY, Forman D, Waskit LA, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins. 2018;10:e163.CrossRefPubMed Park JY, Forman D, Waskit LA, et al. Epidemiology of Helicobacter pylori and CagA-positive infections and global variations in gastric cancer. Toxins. 2018;10:e163.CrossRefPubMed
3.
Zurück zum Zitat Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354–61.CrossRefPubMed Suzuki H, Mori H. World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. J Gastroenterol. 2018;53:354–61.CrossRefPubMed
4.
Zurück zum Zitat Hatakeyama H. Helicobacter pylori CagA and cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:306–16.CrossRefPubMed Hatakeyama H. Helicobacter pylori CagA and cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15:306–16.CrossRefPubMed
5.
Zurück zum Zitat Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Jpn J Cancer Res. 2000;91:774–9.CrossRefPubMedPubMedCentral Kikuchi S, Nakajima T, Kobayashi O, et al. Effect of age on the relationship between gastric cancer and Helicobacter pylori. Jpn J Cancer Res. 2000;91:774–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Ekstom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784–91.CrossRef Ekstom AM, Held M, Hansson LE, et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology. 2001;121:784–91.CrossRef
7.
Zurück zum Zitat Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.CrossRefPubMed Horiuchi Y, Fujisaki J, Yamamoto N, et al. Biological behavior of the intramucosal Helicobacter pylori-negative undifferentiated-type early gastric cancer: comparison with helicobacter pylori-positive early gastric cancer. Gastric Cancer. 2016;19:160–5.CrossRefPubMed
8.
Zurück zum Zitat Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22:e12415.CrossRefPubMedCentral Tsuda M, Asaka M, Kato M, et al. Effect on Helicobacter pylori eradication therapy against gastric cancer in Japan. Helicobacter. 2017;22:e12415.CrossRefPubMedCentral
10.
Zurück zum Zitat Asaka M, Mabe K, Matsushima R, et al. Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin N Am. 2015;44:639–48.CrossRef Asaka M, Mabe K, Matsushima R, et al. Helicobacter pylori eradication to eliminate gastric cancer: the Japanese strategy. Gastroenterol Clin N Am. 2015;44:639–48.CrossRef
11.
Zurück zum Zitat Tsutsumi K, Kusano C, Suzuki S, et al. Diagnostic accuracy of latex agglutination turbidimetric immunoassay in screening adolescents for Helicobacter pylori infection in Japan. Digestion. 2018;98:75–80.CrossRefPubMed Tsutsumi K, Kusano C, Suzuki S, et al. Diagnostic accuracy of latex agglutination turbidimetric immunoassay in screening adolescents for Helicobacter pylori infection in Japan. Digestion. 2018;98:75–80.CrossRefPubMed
12.
Zurück zum Zitat Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42:21–7.CrossRefPubMed Take S, Mizuno M, Ishiki K, et al. Baseline gastric mucosal atrophy is a risk factor associated with the development of gastric cancer after Helicobacter pylori eradication therapy in patients with peptic ulcer diseases. J Gastroenterol. 2007;42:21–7.CrossRefPubMed
13.
Zurück zum Zitat Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMed Wong BC, Lam SK, Wong WM, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA. 2004;291:187–94.CrossRefPubMed
15.
Zurück zum Zitat Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter. 2008;13:278–81.CrossRefPubMed Kato S, Kikuchi S, Nakajima S. When does gastric atrophy develop in Japanese children? Helicobacter. 2008;13:278–81.CrossRefPubMed
16.
Zurück zum Zitat Nozaki K, Shimizu N, Ikehara Y, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–9.CrossRefPubMed Nozaki K, Shimizu N, Ikehara Y, et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Sci. 2003;94:235–9.CrossRefPubMed
17.
Zurück zum Zitat Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92–105.CrossRefPubMed Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology. 2002;123:92–105.CrossRefPubMed
18.
Zurück zum Zitat Akamatsu T, Ichikawa S, Okada S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353–60.CrossRefPubMed Akamatsu T, Ichikawa S, Okada S, et al. Introduction of an examination and treatment for Helicobacter pylori infection in high school health screening. J Gastroenterol. 2011;46:1353–60.CrossRefPubMed
19.
Zurück zum Zitat Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:S16–9.CrossRef Kusano C, Gotoda T, Ishikawa H, et al. The administrative project of Helicobacter pylori infection screening among junior high school students in an area of Japan with a high incidence of gastric cancer. Gastric Cancer. 2017;20:S16–9.CrossRef
20.
Zurück zum Zitat Okuda M, Kamiya S, Booka M, et al. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antigen in children. Pediatr Int. 2013;55:337–41.CrossRefPubMed Okuda M, Kamiya S, Booka M, et al. Diagnostic accuracy of urine-based kits for detection of Helicobacter pylori antigen in children. Pediatr Int. 2013;55:337–41.CrossRefPubMed
21.
Zurück zum Zitat Yamamoto T, Ishii T, Kawakami T, et al. Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis. World J Gastroenterol. 2005;11:412–4.CrossRefPubMedPubMedCentral Yamamoto T, Ishii T, Kawakami T, et al. Reliability of urinary tests for antibody to Helicobacter pylori in patients with pulmonary tuberculosis. World J Gastroenterol. 2005;11:412–4.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Tamamura T, Morita E, Kondo T, et al. Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008–2010. Nagoya J Med Sci. 2012;74:63–70. Tamamura T, Morita E, Kondo T, et al. Prevalence of Helicobacter pylori infection measured with urinary antibody in an urban area of Japan, 2008–2010. Nagoya J Med Sci. 2012;74:63–70.
23.
Zurück zum Zitat Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:818–91. Shimoyama T. Stool antigen tests for the management of Helicobacter pylori infection. World J Gastroenterol. 2013;19:818–91.
24.
Zurück zum Zitat Fukuda Y, Tomita T, Hori K, et al. Evaluation of a novel Helicobacter pylori stool antigen detection kit, Testmate rapid pylori antigen, for rapid diagnosis of Helicobacter pylori infection. Jpn J Med Pharm Sci. 2004;52:469–74. Fukuda Y, Tomita T, Hori K, et al. Evaluation of a novel Helicobacter pylori stool antigen detection kit, Testmate rapid pylori antigen, for rapid diagnosis of Helicobacter pylori infection. Jpn J Med Pharm Sci. 2004;52:469–74.
25.
Zurück zum Zitat Zebala Torrres B, Luceno Y, Lagomarcino AJ, et al. Review: prevalence and dynamics of Helicobacter pylori infection during childhood. Helicobacter. 2017;22:e12399.CrossRef Zebala Torrres B, Luceno Y, Lagomarcino AJ, et al. Review: prevalence and dynamics of Helicobacter pylori infection during childhood. Helicobacter. 2017;22:e12399.CrossRef
26.
Zurück zum Zitat Tanaka Y, Sakata Y, Hara M, et al. Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers. Intern Med. 2017;56:2979–83.CrossRefPubMedPubMedCentral Tanaka Y, Sakata Y, Hara M, et al. Risk factors for Helicobacter pylori infection and endoscopic reflux esophagitis in healthy young Japanese volunteers. Intern Med. 2017;56:2979–83.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Takeshita E, Sakata Y, Hara M, et al. Higher frequency of reflux symptoms and acid-related dyspepsia in females than males regardless of endoscopic esophagitis: cross sectional analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion. 2016;93:266–71.CrossRefPubMed Takeshita E, Sakata Y, Hara M, et al. Higher frequency of reflux symptoms and acid-related dyspepsia in females than males regardless of endoscopic esophagitis: cross sectional analysis of 3,505 Japanese subjects undergoing medical health checkups. Digestion. 2016;93:266–71.CrossRefPubMed
28.
Zurück zum Zitat Fujimoto Y, Furusyo N, Toyoda K, et al. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter. 2007;12:170–6.CrossRefPubMed Fujimoto Y, Furusyo N, Toyoda K, et al. Intrafamilial transmission of Helicobacter pylori among the population of endemic areas in Japan. Helicobacter. 2007;12:170–6.CrossRefPubMed
29.
Zurück zum Zitat Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.CrossRefPubMed Asaka M, Kimura T, Kudo M, et al. Relationship of Helicobacter pylori to serum pepsinogens in an asymptomatic Japanese population. Gastroenterology. 1992;102:760–6.CrossRefPubMed
30.
Zurück zum Zitat Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2014;20:133–8.CrossRefPubMed Okuda M, Osaki T, Lin Y, et al. Low prevalence and incidence of Helicobacter pylori infection in children: a population-based study in Japan. Helicobacter. 2014;20:133–8.CrossRefPubMed
31.
32.
Zurück zum Zitat Rogers AH. The source of infection in the intrafamilial transfer of Streptococcus mutans. Caries Res. 1981;15:26–31.CrossRefPubMed Rogers AH. The source of infection in the intrafamilial transfer of Streptococcus mutans. Caries Res. 1981;15:26–31.CrossRefPubMed
33.
Zurück zum Zitat Seow WK. Early childhood caries. Pesiatr Clin N Am. 2019;65:941–54.CrossRef Seow WK. Early childhood caries. Pesiatr Clin N Am. 2019;65:941–54.CrossRef
34.
Zurück zum Zitat Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65:1439–46.CrossRefPubMedPubMedCentral Murakami K, Sakurai Y, Shiino M, et al. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomized, double-blind study. Gut. 2016;65:1439–46.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Dig Dis Sci. 2017;62:3069–76.CrossRefPubMed Tanabe H, Ando K, Sato K, et al. Efficacy of vonoprazan-based triple therapy for Helicobacter pylori eradication: a multicenter study and a review of the literature. Dig Dis Sci. 2017;62:3069–76.CrossRefPubMed
36.
Zurück zum Zitat Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2018;4:1–7. Takara Y, Endo H, Nakano R, et al. Smoking and drinking did not increase the failure of therapeutic Helicobacter pylori eradication by vonoprazan, clarithromycin, and amoxicillin. Digestion. 2018;4:1–7.
37.
Zurück zum Zitat Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97:212–8.CrossRefPubMed Ozaki H, Harada S, Takeuchi T, et al. Vonoprazan, a novel potassium-competitive acid blocker, should be used for the Helicobacter pylori eradication therapy as first choice: a large sample study of vonoprazan in real world compared with our randomized control trial using second-generation proton pump inhibitors for Helicobacter pylori eradication therapy. Digestion. 2018;97:212–8.CrossRefPubMed
38.
Zurück zum Zitat Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–56.CrossRefPubMed Suzuki S, Gotoda T, Kusano C, et al. The efficacy and tolerability of a triple therapy containing a potassium-competitive acid blocker compared with a 7-day PPI-based low dose clarithromycin triple therapy. Am J Gastroenterol. 2016;111:949–56.CrossRefPubMed
39.
Zurück zum Zitat Khurana R, Fischbach L, Chiba N, et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:423–36.CrossRef Khurana R, Fischbach L, Chiba N, et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther. 2007;25:423–36.CrossRef
40.
Zurück zum Zitat Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guideline for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;23:2453–8. Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guideline for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr. 2017;23:2453–8.
41.
Zurück zum Zitat Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22:e12383.CrossRef Kotilea K, Mekhael J, Salame A, et al. Eradication rate of Helicobacter pylori infection is directly influenced by adherence to therapy in children. Helicobacter. 2017;22:e12383.CrossRef
42.
Zurück zum Zitat Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838–43.CrossRefPubMed Kato S, Konno M, Maisawa S, et al. Results of triple eradication therapy in Japanese children: a retrospective multicenter study. J Gastroenterol. 2004;39:838–43.CrossRefPubMed
43.
Zurück zum Zitat Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:18–90.CrossRef Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pylori in children during the past 9 years. Pediatr Int. 2010;52:18–90.CrossRef
44.
Zurück zum Zitat Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;55:1372–82.CrossRef Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in world health organization regions. Gastroenterology. 2018;55:1372–82.CrossRef
45.
Zurück zum Zitat Montes M, Villalon FN, Eizaguirre FJ, et al. Helicobacter pylori infection in children. Antimicrobial resistance and treatment response. Helicobacter. 2015;20:169–75.CrossRefPubMed Montes M, Villalon FN, Eizaguirre FJ, et al. Helicobacter pylori infection in children. Antimicrobial resistance and treatment response. Helicobacter. 2015;20:169–75.CrossRefPubMed
46.
Zurück zum Zitat Ogata SK, Godoy AP, da Silva Patricio FR, et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645–8.CrossRefPubMed Ogata SK, Godoy AP, da Silva Patricio FR, et al. High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents. J Pediatr Gastroenterol Nutr. 2013;56:645–8.CrossRefPubMed
47.
Zurück zum Zitat Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214–20.CrossRefPubMed Okamura T, Suga T, Nagaya T, et al. Antimicrobial resistance and characteristics of eradication therapy of Helicobacter pylori in Japan: a multi-generational comparison. Helicobacter. 2014;19:214–20.CrossRefPubMed
48.
Zurück zum Zitat Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57–61.CrossRefPubMed Okuda M, Kikuchi S, Mabe K, et al. Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan. Pediatr Int. 2017;59:57–61.CrossRefPubMed
49.
Zurück zum Zitat Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538–43.CrossRefPubMed Mabe K, Okuda M, Kikuchi S, et al. Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan. J Infect Chemother. 2018;24:538–43.CrossRefPubMed
50.
Zurück zum Zitat Adachi T, Matsui S, Watanabe T, et al. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first-line eradication for Helicobacter pylori. Oncology. 2017;93:15–9.CrossRefPubMed Adachi T, Matsui S, Watanabe T, et al. Comparative study of clarithromycin- versus metronidazole-based triple therapy as first-line eradication for Helicobacter pylori. Oncology. 2017;93:15–9.CrossRefPubMed
51.
Zurück zum Zitat Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53:718–24.CrossRefPubMed Kusano C, Gotoda T, Suzuki S, et al. Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children. J Gastroenterol. 2018;53:718–24.CrossRefPubMed
52.
Zurück zum Zitat Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25–40.CrossRefPubMed Gibbons TE, Gold BD. The use of proton pump inhibitors in children: a comprehensive review. Paediatr Drugs. 2003;5:25–40.CrossRefPubMed
Metadaten
Titel
A Helicobacter pylori screening and treatment program to eliminate gastric cancer among junior high school students in Saga Prefecture: a preliminary report
verfasst von
Toshihiko Kakiuchi
Muneaki Matsuo
Hiroyoshi Endo
Aiko Nakayama
Keiko Sato
Ayako Takamori
Kazumi Sasaki
Mitsuhiro Takasaki
Megumi Hara
Yasuhisa Sakata
Masumi Okuda
Shogo Kikuchi
Yuichiro Eguchi
Hirokazu Takahashi
Keizo Anzai
Kazuma Fujimoto
Publikationsdatum
15.02.2019
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 8/2019
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-019-01559-9

Weitere Artikel der Ausgabe 8/2019

Journal of Gastroenterology 8/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.